🏆 Deal of the Week · CW 25/2024
iOnctura raised EUR 80 million in a Series B financing round; the company's post-money valuation was not disclosed. The round closed in June 2024 and was backed by a syndicate of seven institutional investors including VI Partners, Syncona Partners LLP, and Schroders Capital.
iOnctura — key deal facts
| Company | iOnctura |
| Founded | 2017 |
| Headquarters | Geneva, Switzerland |
| Amount raised | EUR 80M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | VI Partners, Syncona Partners LLP, Schroders Capital, M Ventures, Inkef, European Innovation Council, 38 Future Health Fund |
| Sectors | Biotechnology |
Who invested in iOnctura?
The Series B was supported by VI Partners, Syncona Partners LLP, Schroders Capital, M Ventures, Inkef, the European Innovation Council, and 38 Future Health Fund. The investor mix is notable for combining specialist life-science venture funds with a pan-European public innovation mandate, reflecting both commercial and strategic conviction in iOnctura's pipeline. The presence of the European Innovation Council underscores the company's recognition as a high-priority deep-tech asset within the EU's innovation framework.
What does iOnctura do?
iOnctura is a clinical-stage biotechnology company founded in 2017 by Catherine Pickering (Co-Founder and CEO) and Lars van der Veen (Co-Founder and CSO). The company is headquartered in Geneva, Switzerland, and focuses on developing precision oral small molecule therapies for neglected and hard-to-treat cancers. Its lead candidate, roginolisib, is a first-in-class allosteric PI3Kδ modulator designed to reverse immunosuppression within the tumor microenvironment; its second program, cambritaxestat, is an autotaxin inhibitor. Both assets are engineered for low toxicity, with the goal of extending patient healthspan rather than simply prolonging survival.
iOnctura valuation & multiples
Explore the benchmarks: Series B.
Frequently asked questions
How much did iOnctura raise in its Series B?
iOnctura raised EUR 80 million in its Series B financing round, which closed in June 2024.
What is iOnctura's valuation?
iOnctura's post-money valuation was not disclosed as part of this Series B announcement.
Who invested in iOnctura?
The Series B was backed by VI Partners, Syncona Partners LLP, Schroders Capital, M Ventures, Inkef, the European Innovation Council, and 38 Future Health Fund.
When was iOnctura founded and where is it based?
iOnctura was founded in 2017 and is headquartered in Geneva, Switzerland.
Source: original announcement — read the full report.